cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.28652649
title: Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment

description: This study was performed to evaluate patients’ and physicians’ preferences regarding hepatitis C virus (HCV) treatment in Japan, particularly focusing on direct-acting antivirals. Understanding these preferences is important for maintaining adherence to treatment necessary for achieving HCV elimination. A discrete choice experiment was conducted to identify patients’ and physicians’ preferences for HCV treatment in Japan. Eligible participants completed a preference survey <i>via</i> an online questionnaire. Eight attributes and their respective levels – pertaining to dosing regimen/schedule, safety, and out-of-pocket costs – were identified. The primary and secondary endpoints were the relative attribute importance (RAI) and utility value of attribute levels, which were compared between patients and physicians to highlight differences. Both patients (<i>n</i> = 95) and physicians (<i>n</i> = 118) showed the greatest concern for total out-of-pocket treatment costs, followed by safety risks. While patients and physicians generally shared similar treatment preferences, patients placed a higher RAI on total out-of-pocket costs than did physicians (50.4% vs. 39.4%). Conversely, patients assigned lower RAI values to the risks of nasopharyngitis and pruritus (15.2% vs. 17.9% and 11.7% vs. 16.2%, respectively). The RAI for the number of tablets taken daily was higher than that for treatment duration among patients (11.6% vs. 0.2%), but nearly equal among physicians. The study had potential non-response bias, physicians not being actual care providers for surveyed patients, a small sample size, reliance on predefined DCE attributes, and limited participant diversity from online panels. This study highlights the importance of patient-centered care in HCV treatment and the need to raise awareness of the public subsidy for hepatitis, and to ensure an effective access scheme for the patients. Simplifying regimens like once-daily pills and minimal monitoring may enhance treatment convenience. Improved patient–physician communication supports optimized strategies, aiding Japan’s goal of HCV elimination by 2030.
DOI: 10.6084/m9.figshare.28652649.v1
title: Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment

description: This study was performed to evaluate patients’ and physicians’ preferences regarding hepatitis C virus (HCV) treatment in Japan, particularly focusing on direct-acting antivirals. Understanding these preferences is important for maintaining adherence to treatment necessary for achieving HCV elimination. A discrete choice experiment was conducted to identify patients’ and physicians’ preferences for HCV treatment in Japan. Eligible participants completed a preference survey <i>via</i> an online questionnaire. Eight attributes and their respective levels – pertaining to dosing regimen/schedule, safety, and out-of-pocket costs – were identified. The primary and secondary endpoints were the relative attribute importance (RAI) and utility value of attribute levels, which were compared between patients and physicians to highlight differences. Both patients (<i>n</i> = 95) and physicians (<i>n</i> = 118) showed the greatest concern for total out-of-pocket treatment costs, followed by safety risks. While patients and physicians generally shared similar treatment preferences, patients placed a higher RAI on total out-of-pocket costs than did physicians (50.4% vs. 39.4%). Conversely, patients assigned lower RAI values to the risks of nasopharyngitis and pruritus (15.2% vs. 17.9% and 11.7% vs. 16.2%, respectively). The RAI for the number of tablets taken daily was higher than that for treatment duration among patients (11.6% vs. 0.2%), but nearly equal among physicians. The study had potential non-response bias, physicians not being actual care providers for surveyed patients, a small sample size, reliance on predefined DCE attributes, and limited participant diversity from online panels. This study highlights the importance of patient-centered care in HCV treatment and the need to raise awareness of the public subsidy for hepatitis, and to ensure an effective access scheme for the patients. Simplifying regimens like once-daily pills and minimal monitoring may enhance treatment convenience. Improved patient–physician communication supports optimized strategies, aiding Japan’s goal of HCV elimination by 2030.
DOI: 10.6084/m9.figshare.28920753.v1
title: The patient journey and burden of disease in <i>demodex</i> blepharitis in the United States

description: <i>Demodex</i> blepharitis (DB) is a chronic eyelid disease caused by an infestation of <i>Demodex</i> mites. The objective of this chart audit study was to characterize the patient journey and burden of illness associated with DB from an eye-care provider's perspective. Retrospective medical data for patients with a confirmed diagnosis of DB were anonymously collected via ophthalmologists and optometrists in the US (collectively eye-care providers [ECPs]), in June-July 2022. Each eligible ECP completed a questionnaire and provided chart abstractions of 1-5 medical charts of patients with DB in an electronic case report form. All ECPs (N = 61) were ophthalmologists or optometrists who worked primarily in office-based private practices (97%). Data from 192 medical charts of patients with an ECP-confirmed diagnosis of DB were abstracted and their demographics included 54% males and 71% Caucasians. The mean time (±SD) since diagnosis was 11 (±9.0) years. Over 40% of patients were not examined for DB at initial presentation, and the average time from initial presentation to a definitive diagnosis for DB was 6.5 months. After DB diagnosis and across the period of observation until the time of the study, patients had a mean (±SD) of 3.2 (±2.8) follow-up visits due to DB and continued to use multiple off-label prescription and over-the-counter therapies for symptom management. Medical records may be incomplete or inconsistently reported and subject to recall bias. The patient journey is lengthy with multiple challenges, including delay in DB diagnosis and recurring DB symptoms, underlining an urgent need for action to improve diagnosis and treatment of DB. <i>Demodex</i> blepharitis, caused by <i>Demodex</i> mite infestation, is a prevalent chronic disease of the eyelid. This study examined the patient experiences and the burden of the disease from the eye-care providers' perspectives. Many patients experienced delays in diagnosis, with over 40% were not examined for <i>Demodex</i> blepharitis initially. On average, diagnosis took 6.5 months from the initial presentation. Patients required multiple follow-up visits (average 3.2) and used various management therapies after diagnosis. The results underscore the impact of <i>Demodex</i> blepharitis and emphasize the importance of early detection and improved treatment strategies to better patient experiences and outcomes.
DOI: 10.15468/dl.mwruf6
title: Occurrence Download

description: A dataset containing 68181 records in GBIF matching the query:
SELECT
 '32' AS fish_cell,
 GBIF_MGRSCode(1000, decimalLatitude, decimalLongitude, 0) AS cell, -- NO randomization
 COUNT(DISTINCT speciesKey) AS species_richness
 FROM occurrence
 WHERE hasCoordinate = TRUE
 AND speciesKey IS NOT NULL
 AND NOT ARRAY_CONTAINS(issue, 'ZERO_COORDINATE')
 AND NOT ARRAY_CONTAINS(issue, 'COORDINATE_OUT_OF_RANGE')
 AND NOT ARRAY_CONTAINS(issue, 'COORDINATE_INVALID')
 AND NOT ARRAY_CONTAINS(issue, 'COUNTRY_COORDINATE_MISMATCH')
 AND decimalLatitude &gt;= -33.06103686093294
 AND decimalLatitude &lt;= -28.773895969281842
 AND decimalLongitude &gt;= 146.15102397859218
 AND decimalLongitude &lt;= 155.85126321428865
 AND "year" &gt;= 2015
 AND "year" &lt;= 2026
 AND (coordinateUncertaintyInMeters &lt;= 100 OR coordinateUncertaintyInMeters IS NULL)
 GROUP BY fish_cell, cell

 The dataset's 68181 records were derived from 151 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003236-260120142942310/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.2dard6
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{"type":"and","predicates":[{"type":"within","geometry":"POLYGON ((100.146 2.303179, 100.075681 2.29761, 100.007095 2.281042, 99.94193199999999 2.253882, 99.88179700000001 2.216799, 99.82817300000001 2.170709, 99.78237900000001 2.116745, 99.745542 2.056238, 99.71857 1.990678, 99.702124 1.92168, 99.696609 1.850943, 99.70216000000001 1.780208, 99.718637 1.711218, 99.745634 1.645671, 99.782487 1.585179, 99.828287 1.531233, 99.881905 1.48516, 99.942024 1.448093, 100.007162 1.420945, 100.075716 1.404385, 100.146 1.398819, 100.216284 1.404385, 100.284838 1.420945, 100.349976 1.448093, 100.410095 1.48516, 100.463713 1.531233, 100.509513 1.585179, 100.546366 1.645671, 100.573363 1.711218, 100.58984 1.780208, 100.595391 1.850943, 100.589876 1.92168, 100.57343 1.990678, 100.546458 2.056238, 100.509621 2.116745, 100.463827 2.170709, 100.410203 2.216799, 100.350068 2.253882, 100.284905 2.281042, 100.216319 2.29761, 100.146 2.303179))"},{"type":"equals","key":"CLASS_KEY","value":"212","matchCase":false},{"type":"greaterThanOrEquals","key":"YEAR","value":"2015","matchCase":false},{"type":"not","predicate":{"type":"in","key":"BASIS_OF_RECORD","values":["MATERIAL_CITATION","MATERIAL_SAMPLE","PRESERVED_SPECIMEN"],"matchCase":false}},{"type":"lessThanOrEquals","key":"COORDINATE_UNCERTAINTY_IN_METERS","value":"10000","matchCase":false},{"type":"equals","key":"LICENSE","value":"CC BY 4.0","matchCase":false}]}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003268-260120142942310/datasets/export for details.
DOI: 10.15468/dl.wkp9a8
title: Occurrence Download

description: A dataset listing the 215 species recorded in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((-55.52453 -62.32655,-63.98326 -63.68969,-69.2008 -66.32589,-69.99133 -67.44295,-68.80553 -69.74878,-67.78097 -70.53785,-65.88855 -69.99987,-66.38655 -67.47437,-64.99214 -66.22153,-62.51881 -65.02576,-59.71895 -64.03202,-56.95264 -63.20407,-56.95264 -62.92507,-55.52453 -62.32655))",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Bryophyta"
 ]
}

 The dataset's 215 records were derived from 38 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003238-260120142942310/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.u8rfwx
title: Occurrence Download

description: A dataset containing 19 species occurrences available in GBIF matching the query:
{"type":"and","predicates":[{"type":"within","geometry":"POLYGON ((-76.61199999999999 8.019100999999999, -76.682951 8.013529, -76.75215 7.996951, -76.817887 7.969776, -76.87854 7.932676, -76.932613 7.886565, -76.978774 7.832584, -77.01588700000001 7.772062, -77.043041 7.706494, -77.059572 7.637494, -77.065077 7.566765, -77.059426 7.496046, -77.04276400000001 7.42708, -77.015506 7.361562, -76.978325 7.301105, -76.932141 7.247195, -76.878091 7.201156, -76.817505 7.164119, -76.751873 7.136995, -76.682805 7.12045, -76.61199999999999 7.114889, -76.541195 7.12045, -76.472127 7.136995, -76.40649500000001 7.164119, -76.34590900000001 7.201156, -76.291859 7.247195, -76.24567500000001 7.301105, -76.208494 7.361562, -76.181236 7.42708, -76.164574 7.496046, -76.158923 7.566765, -76.164428 7.637494, -76.180959 7.706494, -76.208113 7.772062, -76.245226 7.832584, -76.291387 7.886565, -76.34546 7.932676, -76.406113 7.969776, -76.47185 7.996951, -76.541049 8.013529, -76.61199999999999 8.019100999999999))"},{"type":"equals","key":"CLASS_KEY","value":"212","matchCase":false},{"type":"greaterThanOrEquals","key":"YEAR","value":"2015","matchCase":false},{"type":"not","predicate":{"type":"in","key":"BASIS_OF_RECORD","values":["MATERIAL_CITATION","MATERIAL_SAMPLE","PRESERVED_SPECIMEN"],"matchCase":false}},{"type":"lessThanOrEquals","key":"COORDINATE_UNCERTAINTY_IN_METERS","value":"10000","matchCase":false},{"type":"equals","key":"LICENSE","value":"CC BY 4.0","matchCase":false}]}

 The dataset includes 19 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003269-260120142942310/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.tv62db
title: Occurrence Download

description: A dataset containing 25 species occurrences available in GBIF matching the query:
{
 "and" : [
 "BasisOfRecord is Specimen",
 "Country is Mexico",
 "TaxonKey is Selenicereus hondurensis"
 ]
}

 The dataset includes 25 records from 8 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003270-260120142942310/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/hhj5aj
title: Two new species of genus Bactrocera Macquart (Diptera: Tephritidae: Dacinae: Dacini) from northern Himalayas and new records of host plants, distribution or variation in three other species in India

description: This dataset contains the digitized treatments in Plazi based on the original journal article Singh, Maneesh Pal, Hancock, David Lawrence (2025): Two new species of genus Bactrocera Macquart (Diptera: Tephritidae: Dacinae: Dacini) from northern Himalayas and new records of host plants, distribution or variation in three other species in India. Zootaxa 5666 (2): 175-194, DOI: 10.11646/zootaxa.5666.2.2, URL: http://dx.doi.org/10.11646/zootaxa.5360.3.8AbstractTwo new species of genus Bactrocera Macquart, Bactrocera (Bactrocera) viraktamathi Maneesh & Hancock, sp. nov. and Bactrocera (Javadacus) barakzaii Maneesh & Hancock, sp. nov. are described from the Himalayan region of India and keys to all species of the Bactrocera latifrons group and Indian species of subgenus Javadacus Hardy are provided. Variation in B. prabhakari Maneesh, Gupta & Hancock is also discussed. Bactrocera venifica (Hering) is recorded for the first time from India and new host plants for B. divenderi Maneesh, Hancock & Prabhakar are noted.
DOI: 10.15468/dl.8dumem
title: Occurrence Download

description: A dataset containing 63 species occurrences available in GBIF matching the query:
{
 "and" : [
 "OccurrenceStatus is Present",
 "TaxonKey is Platyrrhinus masu"
 ]
}

 The dataset includes 63 records from 5 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003271-260120142942310/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.29175338
title: Associations between military sexual trauma and chronic pain in men and women active military members and veterans

description: We evaluated gendered risks and the associations between demographics, anxiety, and depressive symptoms, military sexual trauma (MST), and severe pain in Canadian military personnel and veterans. A cross-sectional sample of 328 veterans and military members with chronic pain completed confidential surveys, including demographics, disability, pain location, and intensity, as well as a Patient Health Questionnaire (PHQ-4). We evaluated gendered exposures (rates, odds ratios), associations between MST and severe pain (logistic regression), and associations with pain severity and PHQ-4 (linear regression), adjusting for age, race, and education. We found high levels of chronic pain and disability for women and men (6.8 or 6.9/10), PHQ-4 scores (6.6 or 6.2/12), and SANE scores (11% or 10%). Women reported higher exposure to MST (e.g. 69% for sexual harassment, 76% for emotional abuse) than men (8% and 13%). Odds of severe pain were not gendered (OR = 1.05). Physical abuse (<i>β</i> = 1.09, <i>p</i> = .030) and gender discrimination (<i>β</i> = 1.10, <i>p</i> = .033) were associated with higher PHQ-4 scores. Sexual harassment was not independently associated (OR = 1.57, <i>p</i> = .354) with chronic pain, but was associated with increased anxiety and depressive symptoms (<i>β</i> = 1.06, <i>p</i> = .016). Higher PHQ-4 scores were significantly associated with higher pain scores (<i>β</i> = 0.18, <i>p</i> &lt; .001). MST exposures are much more common among women, but the associations of MST with severe pain and PHQ-4 scores are similar across genders. Differences in operational trauma and occupational trauma may influence occupational stress injuries and chronic pain.
DOI: 10.6084/m9.figshare.29175338.v1
title: Associations between military sexual trauma and chronic pain in men and women active military members and veterans

description: We evaluated gendered risks and the associations between demographics, anxiety, and depressive symptoms, military sexual trauma (MST), and severe pain in Canadian military personnel and veterans. A cross-sectional sample of 328 veterans and military members with chronic pain completed confidential surveys, including demographics, disability, pain location, and intensity, as well as a Patient Health Questionnaire (PHQ-4). We evaluated gendered exposures (rates, odds ratios), associations between MST and severe pain (logistic regression), and associations with pain severity and PHQ-4 (linear regression), adjusting for age, race, and education. We found high levels of chronic pain and disability for women and men (6.8 or 6.9/10), PHQ-4 scores (6.6 or 6.2/12), and SANE scores (11% or 10%). Women reported higher exposure to MST (e.g. 69% for sexual harassment, 76% for emotional abuse) than men (8% and 13%). Odds of severe pain were not gendered (OR = 1.05). Physical abuse (<i>β</i> = 1.09, <i>p</i> = .030) and gender discrimination (<i>β</i> = 1.10, <i>p</i> = .033) were associated with higher PHQ-4 scores. Sexual harassment was not independently associated (OR = 1.57, <i>p</i> = .354) with chronic pain, but was associated with increased anxiety and depressive symptoms (<i>β</i> = 1.06, <i>p</i> = .016). Higher PHQ-4 scores were significantly associated with higher pain scores (<i>β</i> = 0.18, <i>p</i> &lt; .001). MST exposures are much more common among women, but the associations of MST with severe pain and PHQ-4 scores are similar across genders. Differences in operational trauma and occupational trauma may influence occupational stress injuries and chronic pain.
DOI: 10.6084/m9.figshare.29716431
title: Opioid analgesics for chronic noncancer pain in patients prescribed opioid agonist therapy or with opioid use disorder: A systematic review

description: Opioid use disorder (OUD) is a growing public health concern in North America, often coexisting with chronic noncancer pain (CNCP). Managing both conditions presents unique challenges, highlighting the need for evidence to guide decision making. The study aimed to conduct a systematic review that summarizes evidence on the efficacy, effectiveness, and safety of opioid analgesics alone or in combination with opioid agonist therapy (OAT) to manage CNCP in people with OUD or with a history of OUD. We searched MEDLINE, Embase, PsycINFO, CINAHL and AMED from inception to July 2023 for randomized studies and up to January 2025 for non-randomized studies that explored the efficacy, effectiveness, and safety of opioids for people living with chronic pain and current or prior OUD. We assessed the risk of bias in included studies, evaluated the quality of evidence using the GRADE approach, and provided a narrative summary of treatment effects. Our search identified 15,988 unique citations, of which six observational studies were deemed eligible to inform safety outcomes for review, while no observational studies or RCTs met the eligibility criteria for efficacy or effectiveness outcomes. The likelihood of suicidality was twice as high in CNCP patients with OUD receiving long-term opioid analgesics compared to those without OUD (absolute risk increase: 127; 95% CI: 36 to 249 more participants with suicidality in 1,000 participants; moderate certainty evidence). Compared to opioid analgesics alone, the risk of fatal opioid-related overdose may decrease in patients with CNCP and OUD who receive both opioid analgesics and OAT (absolute risk reduction: 60; 95%CI: 18 to 94 fewer deaths in 1,000 participants; low certainty evidence). There is a paucity of evidence to inform practice and policy regarding opioid analgesic prescribing amongst people with OUD. Existing evidence suggests that such prescribing is associated with a higher risk of suicidality, while the use of OAT together with opioid analgesics in this population may be protective against fatal overdose. Further observational and trial research is needed to clarify the benefits and harms of opioid analgesics for CNCP patients with OUD.
DOI: 10.6084/m9.figshare.29716431.v1
title: Opioid analgesics for chronic noncancer pain in patients prescribed opioid agonist therapy or with opioid use disorder: A systematic review

description: Opioid use disorder (OUD) is a growing public health concern in North America, often coexisting with chronic noncancer pain (CNCP). Managing both conditions presents unique challenges, highlighting the need for evidence to guide decision making. The study aimed to conduct a systematic review that summarizes evidence on the efficacy, effectiveness, and safety of opioid analgesics alone or in combination with opioid agonist therapy (OAT) to manage CNCP in people with OUD or with a history of OUD. We searched MEDLINE, Embase, PsycINFO, CINAHL and AMED from inception to July 2023 for randomized studies and up to January 2025 for non-randomized studies that explored the efficacy, effectiveness, and safety of opioids for people living with chronic pain and current or prior OUD. We assessed the risk of bias in included studies, evaluated the quality of evidence using the GRADE approach, and provided a narrative summary of treatment effects. Our search identified 15,988 unique citations, of which six observational studies were deemed eligible to inform safety outcomes for review, while no observational studies or RCTs met the eligibility criteria for efficacy or effectiveness outcomes. The likelihood of suicidality was twice as high in CNCP patients with OUD receiving long-term opioid analgesics compared to those without OUD (absolute risk increase: 127; 95% CI: 36 to 249 more participants with suicidality in 1,000 participants; moderate certainty evidence). Compared to opioid analgesics alone, the risk of fatal opioid-related overdose may decrease in patients with CNCP and OUD who receive both opioid analgesics and OAT (absolute risk reduction: 60; 95%CI: 18 to 94 fewer deaths in 1,000 participants; low certainty evidence). There is a paucity of evidence to inform practice and policy regarding opioid analgesic prescribing amongst people with OUD. Existing evidence suggests that such prescribing is associated with a higher risk of suicidality, while the use of OAT together with opioid analgesics in this population may be protective against fatal overdose. Further observational and trial research is needed to clarify the benefits and harms of opioid analgesics for CNCP patients with OUD.